Category Pharmacy Development

GSK and Pfizer launch new HIV company

Nov4

Nov 05, 2009 (Datamonitor via COMTEX) GlaxoSmithKline, a UK-based pharmaceutical group, and Pfizer, a US-based pharmaceutical group, have launched ViiV Healthcare, a new specialist HIV company.ViiV Healthcare has 10 medicines currently available including therapies such as Epzicom/Kivexa and Selzentry/Celsentri. The company also has a pipeline of seven targeted medicines, including five compounds in Phase II […]

Theratechnologies’ NDA for Tesamorelin to be Reviewed by an FDA Advisory Committee

Nov4

MONTREAL, CANADA (MARKET WIRE) 11/05/09 Theratechnologies (TSX: TH) today announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration ("FDA") will review Theratechnologies’ NDA for tesamorelin in the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy. The role of the Advisory Committee, which is tentatively scheduled to […]

Hercules Technology Announces Third Quarter 2009 Financial Results and Declared a $0.30 Cash Dividend

Nov4

Net interest margin of 13.68% Received SBA approval to complete second SBIC license application Various portfolio companies achieved key milestones during and after the quarter including one pending acquisition and one completed IPO PALO ALTO, Calif.(BUSINESS WIRE) Hercules Technology Growth Capital, Inc. (NASDAQ: HTGC), the leading specialty finance company providing venture debt and equity to […]

Targacept Reports Third Quarter 2009 Financial Results

Nov4

WINSTON-SALEM, N.C.(BUSINESS WIRE) Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics?, today reported its financial results for the third quarter ended September 30, 2009. Targacept reported net income of $1.3 million for the third quarter of 2009, compared to a net loss of $7.6 million […]

Somaxon Pharmaceuticals Reports 2009 Third Quarter Financial Results

Nov4

Conference call scheduled today at 1:30 p.m. PT; Simultaneous webcast at http://investors.somaxon.com/eventdetail.cfm SAN DIEGO(BUSINESS WIRE) Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX), a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today […]

Millipore Reports Third Quarter 2009 Financial Results

Nov4

Company generates 7 percent organic revenue growth and $112 million of free cash flow BILLERICA, Mass.(BUSINESS WIRE) Millipore Corporation (NYSE:MIL), a leading provider of technologies, tools and services for the global life science industry, today reported financial results for its third quarter ended October 3, 2009. Revenues for the third quarter grew 4 percent from […]

First Patient Enrolled in Phase 3 Trials of Genzyme Oral Capsule for Gaucher Disease

Nov4

2009 NOV 5 – (NewsRx.com) Genzyme Corporation (NASDAQ: GENZ) announced that the company has begun enrollment in the first of two global, multi-center, phase 3 trials of Genz-112638, a potential new oral therapy for Gaucher disease type 1. The two multi-national, multi-center trials are being conducted to evaluate the safety and efficacy of the small […]

Threshold Pharmaceuticals Reports Third Quarter 2009 Financial Results

Nov4

REDWOOD CITY, Calif., Nov. 5, 2009 (GLOBE NEWSWIRE) Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today reported financial results for the third quarter ended September 30, 2009.The net loss for the third quarter of 2009 was $6.2 million compared to $4.6 million for the third quarter of 2008.Research and development expenses were $4.0 million for the third quarter […]

Isis Reports Financial Results and Highlights for Third Quarter of 2009

Nov4

CARLSBAD, Calif., Nov. 5 /PRNewswire-FirstCall/ Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced its financial results for the third quarter ended September 30, 2009. For the quarter, Isis reported a net loss of $3.4 million and a net operating loss of $6.9 million. In addition, for the first nine months of 2009, Isis reported net income […]

Transcept wins notice of allowance for sleep disorder drug

Nov4

Nov 05, 2009 (Datamonitor via COMTEX) Transcept Pharmaceuticals, a specialty pharmaceutical company, has received a notice of allowance from the US Patent and Trademark Office for claims under US patent application, which covers the use of Intermezzo, the company’s lead product candidate. Once issued, this patent will expire in February 2025.Under the terms of the […]